Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.'s (HKG:6990) 27% Price Boost Is Out Of Tune With Revenues
Apr 13
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Healthcare Sector Analysis
UpdatedApr 15, 2025
DataAggregated Company Financials
Companies204
- 7D14.8%
- 3M24.1%
- 1Y19.9%
- YTD17.1%
Over the last 7 days, the Healthcare industry has dropped 7.9%, driven by declines in Wuhan YZY Biopharma and Tycoon Group Holdings of 23% and 8.4%, respectively. In contrast, Akeso has gained 34%. In the past year, the industry has gained 15%. As for the next few years, earnings are expected to grow by 29% per annum.
Sector Valuation and Performance
Has the Hong Kong Healthcare Sector valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 15 Apr 2025 | HK$1.6t | HK$1.4t | HK$32.2b | 14x | 49.6x | 1.1x |
| Thu, 13 Mar 2025 | HK$1.5t | HK$1.4t | HK$29.5b | 11.9x | 50.9x | 1.1x |
| Sat, 08 Feb 2025 | HK$1.3t | HK$1.4t | HK$29.0b | 11.2x | 46.5x | 1x |
| Mon, 06 Jan 2025 | HK$1.3t | HK$1.4t | HK$28.8b | 11.4x | 45.4x | 0.9x |
| Wed, 04 Dec 2024 | HK$1.4t | HK$1.4t | HK$29.2b | 12.3x | 47.2x | 1x |
| Fri, 01 Nov 2024 | HK$1.4t | HK$1.4t | HK$29.4b | 12.2x | 46.7x | 0.9x |
| Sun, 29 Sep 2024 | HK$1.4t | HK$1.5t | HK$30.8b | 12.5x | 45.8x | 1x |
| Tue, 27 Aug 2024 | HK$1.2t | HK$1.4t | HK$26.4b | 10.6x | 45.6x | 0.8x |
| Thu, 25 Jul 2024 | HK$1.2t | HK$1.4t | HK$27.4b | 10.9x | 43.7x | 0.8x |
| Sat, 22 Jun 2024 | HK$1.3t | HK$1.4t | HK$28.6b | 11x | 44.5x | 0.9x |
| Mon, 20 May 2024 | HK$1.4t | HK$1.4t | HK$28.7b | 12.1x | 49.1x | 1x |
| Wed, 17 Apr 2024 | HK$1.3t | HK$1.4t | HK$28.4b | 11x | 44.6x | 0.9x |
| Fri, 15 Mar 2024 | HK$1.4t | HK$1.4t | HK$28.3b | 11.7x | 48.6x | 1x |
| Sun, 11 Feb 2024 | HK$1.3t | HK$1.4t | HK$25.9b | 11.4x | 48.4x | 0.9x |
| Tue, 09 Jan 2024 | HK$1.5t | HK$1.4t | HK$26.0b | 12.7x | 56.1x | 1x |
| Thu, 07 Dec 2023 | HK$1.6t | HK$1.4t | HK$26.3b | 12.3x | 60x | 1.1x |
| Sat, 04 Nov 2023 | HK$1.6t | HK$1.4t | HK$25.0b | 13.1x | 65.7x | 1.2x |
| Mon, 02 Oct 2023 | HK$1.6t | HK$1.4t | HK$24.6b | 12.6x | 64.9x | 1.1x |
| Wed, 30 Aug 2023 | HK$1.6t | HK$1.4t | HK$19.0b | 12.9x | 84.5x | 1.2x |
| Fri, 28 Jul 2023 | HK$1.7t | HK$1.4t | HK$2.6b | 14x | 674.1x | 1.3x |
| Sun, 25 Jun 2023 | HK$1.6t | HK$1.4t | HK$3.0b | 14x | 530.1x | 1.2x |
| Tue, 23 May 2023 | HK$1.7t | HK$1.4t | HK$3.3b | 15.2x | 517.3x | 1.3x |
| Thu, 20 Apr 2023 | HK$2.0t | HK$1.4t | HK$3.8b | 14.6x | 524.5x | 1.4x |
| Sat, 18 Mar 2023 | HK$1.9t | HK$1.3t | HK$1.6b | 15x | 1161.6x | 1.4x |
| Mon, 13 Feb 2023 | HK$2.0t | HK$1.4t | HK$2.2b | 15.5x | 925.1x | 1.5x |
| Wed, 11 Jan 2023 | HK$2.0t | HK$1.4t | HK$2.2b | 15.4x | 912.1x | 1.5x |
| Fri, 09 Dec 2022 | HK$1.9t | HK$1.3t | HK$2.1b | 13.9x | 890.3x | 1.4x |
| Sun, 06 Nov 2022 | HK$1.7t | HK$1.3t | HK$1.3b | 12.5x | 1286.6x | 1.3x |
| Tue, 04 Oct 2022 | HK$1.5t | HK$1.3t | HK$3.7b | 12.9x | 397.3x | 1.1x |
| Thu, 01 Sep 2022 | HK$1.7t | HK$1.3t | HK$7.7b | 14.4x | 223.6x | 1.3x |
| Sat, 30 Jul 2022 | HK$1.8t | HK$1.3t | -HK$1,006,326,998.00 | 13.9x | -1799.6x | 1.4x |
| Mon, 27 Jun 2022 | HK$1.9t | HK$1.3t | -HK$424,856,714.00 | 14.4x | -4545.8x | 1.5x |
| Wed, 25 May 2022 | HK$1.6t | HK$1.3t | -HK$2,289,616,911.00 | 13.5x | -692.7x | 1.2x |
| Fri, 22 Apr 2022 | HK$1.6t | HK$1.4t | -HK$2,498,893,189.00 | 13x | -652.1x | 1.2x |
Price to Earnings Ratio
-652.1x
Current Industry PE
- Investors are pessimistic on the Hong Kong Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 45.6x which is lower than its 3-year average PE of 100x.
- The industry is trading close to its 3-year average PS ratio of 1.1x.
Past Earnings Growth
- Total earnings for the Healthcare industry have gone up over the last three years, and the industry is now profitable.
- Revenues have remained mostly flat. This means that the industry has become more efficient since profits are increasing while sales have been flat.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare sector?
| HK Market | 8.17% | |
| Healthcare | 14.77% | |
| Biotech | 22.06% | |
| Life Sciences | 15.90% | |
| Healthtech | 15.21% | |
| Pharma | 11.71% | |
| Medical Equipment | 9.28% | |
| Healthcare Services | 8.57% | |
Industry PE
- Investors are most optimistic about the Life Sciences industry which is trading above its 3-year average PE ratio of 35.8x.
- Analysts are expecting annual earnings growth of 33.8%, which is higher than its past year's earnings decline of 1.3% per year.
Forecasted Growth
- Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 56% over the next 5 years.
- This is better than its past earnings growth rate of 8.4% per year.
- In contrast, the Pharma industry is expected to see its earnings grow by 12% per year over the next few years.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 9926 Akeso | HK$87.70 | 30.4% +HK$18.4b | 86.6% | PS34.9x | |
| 2269 WuXi Biologics (Cayman) | HK$21.20 | 19.0% +HK$13.0b | 62.6% | PE24.1x | |
| 6990 Sichuan Kelun-Biotech Biopharmaceutical | HK$310.20 | 19.7% +HK$11.6b | 134.1% | PS34.4x | |
| 1801 Innovent Biologics | HK$48.35 | 15.0% +HK$10.3b | 39.3% | PS7.9x | |
| 1093 CSPC Pharmaceutical Group | HK$5.60 | 14.5% +HK$8.1b | -3.6% | PE14x |
